drugset / Trial / NCT03068065
Antidiabetic Effects on Intrahepatic Fat
Phase 4
Completed
87 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RandomizedParallel-groupOpen-labelTreatment
Summary
This was a 24-week single-center, open-label, parallel controlled group comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease.
Timeline
- Start
- 2014-05
- Primary completion
- 2014-11
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gliclazide | Small molecule | 120 mg | — |
| Comparator | Liraglutide | Peptide | 1.8 mg | — |
| Comparator | Metformin | Small molecule | 1000 mg | — |